CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.

ABSTRACT:

Aims

Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients.

Methods

In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements of rituximab concentrations (pharmacokinetics), CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were made. Rituximab pharmacokinetics was described using a 2-compartment model, and CD4+ cell counts and DAS28 measurements were described using indirect turnover and direct Emax pharmacokinetic-pharmacodynamic models, res

SUBMITTER: Bensalem A 

PROVIDER: S-EPMC6955400 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature